The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs-Reference-Cited by-同舟云学术

The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs

Published:2022-01-24 Issue:3 Volume:22 Page:317-321
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Zettler Marjorie E.¹^ORCID

Affiliation:

1. Department of Clinical Science, Regor Pharmaceuticals, Inc., Cambridge, MA, USA

Funder

received no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2032664

Reference23 articles.

1. Cancer Statistics, 2021

2. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities

3. Public Law 108–155, 108th Congress. Pediatric research equity act of 2003. 2003 Dec 3. Available from: https://uscode.house.gov/statutes/pl/108/155.pdf

4. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers

5. Off‐label prescribing of targeted anticancer therapy at a large pediatric cancer center

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The RACE Act and Pediatric Trials of Adult Cancer Drugs;Pediatrics;2024-09-04

2. Conducting Drug Treatment Trials in Children: Opportunities and Challenges;Pharmaceutical Medicine;2024-05

3. Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship;Pediatric Blood & Cancer;2024-02-26

4. Pediatric oncology drug development and dosage optimization;Frontiers in Oncology;2024-01-29

5. Collaborative Innovations in Childhood Cancer Therapies;Handbook of Experimental Pharmacology;2024